Company s Liver Cancer Drug Candidate IP Portfolio strengthened
Company provides operational update on strategic opportunities
NEW YORK, April 14, 2023 /PRNewswire/ Q BioMed Inc. a biotech. | April 14, 2023
/PRNewswire/ Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical.
/PRNewswire/ Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it has converted its.
NEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued
/PRNewswire/ Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical.